Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment

Calum J McMullen, Rachel A Wood, Margaret R Cunningham, Susan Currie

Research output: Contribution to journalMeeting abstractpeer-review

6 Citations (Scopus)
29 Downloads (Pure)


The tyrosine kinase inhibitor sunitinib has dramatically improved cancer therapy in recent years however, this success has been marred by reports of associated cardiotoxicity. The effect of sunitinib on cardiac myocyte function has been extensively studied, yet little is known of wider ranging effects on cardiac non-myocytes. Cardiac fibroblasts (CF) are the most abundant cell type within the heart and are responsible for maintaining cardiac structure via extracellular matrix remodelling and for facilitating synchronised cardiac contraction. Here, we have investigated whether chronic sunitinib treatment adversely affects CF viability.
Original languageEnglish
Pages (from-to)A6-A7
Number of pages2
Issue numbersuppl 4
Publication statusPublished - 1 May 2019
Event14th British Society of Cardiovascular Magnetic Resonance Annual Meeting 2019 - Oxford, United Kingdom
Duration: 26 Mar 201927 Mar 2019


  • tyrosine kinase inhibitor
  • sunitinib
  • cardiac fibroblast


Dive into the research topics of 'Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment'. Together they form a unique fingerprint.

Cite this